Skip to main content

Commercial Division

  • Chapter
Drug and Biological Development
  • 1864 Accesses

Successful products require substantial, consistent investment and a multifaceted approach to development and commercialization. Multiple strategies, real product-specific advantages that differentiate a product from key competitors, and the marketing muscle necessary to achieve share of voice are key to long-term success. Effective prelaunch planning and execution is required to shape and prepare the market and to ensure rapid adoption at launch. Companies are constantly faced with a series of choices. How those choices are made will ultimately determine the future success of the brand. There is substantial cost to developing and marketing potential blockbusters, and early commercial analysis and input is critical to the process. Prelaunch investments can be significant. Through a partnership involving research, clinical development, and commercial, we can hope to optimize the decision-making process, reduce the risk of investment, effectively shape products and their markets for launch success, and focus on areas of opportunity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. PhRMA Member Companies' R&D Expenditures for 2001 is estimated

    Google Scholar 

  2. U.S. Food and Drug Administration 2002. IDEC's Zeralin (Feb.), Gilead's Hepsera (Sep.), Seron's Rebif (Mar.), Amgen's Neulastaâ„¢ (Jan.), Pfizer's Vfend (May), Novartis' Zelnorm (July), Astrazerer's Faslodex (April) plus 4 others

    Google Scholar 

  3. Blauvelt B. Benchmarks for blockbuster launches. Pharmaceutical Executive, Vol. 23, pg. 53, Feb 2003

    Google Scholar 

  4. Daly, M. Lolassa; Pharmaceutical Executive Supplement, Vol. 24 March 2004

    Google Scholar 

  5. Fox, S. Market research 101. Pharmaceutical Executive. Vol. 21, May 2001

    Google Scholar 

  6. Gregson N, Sparrowhawk K, Muaskopf J, Paul J. Pricing medicines: Theory and practice, challenges and opportunities. Nature Drug Discovery 2005;4(2):121–130

    Article  CAS  Google Scholar 

  7. Anonymous. Product Launches Report. Personal communication. 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Lytle, T. (2007). Commercial Division. In: Evens, R.P. (eds) Drug and Biological Development. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69094-0_10

Download citation

Publish with us

Policies and ethics